Unrelated cord blood transplantation for severe combined immunodeficiency and other primary immunodeficiencies

Area of Science:

• Pediatric Hematology/Oncology
• Immunology
• Transplantation Science

Background:

• Hematopoietic stem cell transplantation (HCT) is the primary treatment for severe primary immunodeficiencies (PIDs) in children.
• Many pediatric PID patients lack a suitable HLA-identical sibling donor, necessitating alternative transplant options.
• Experience with umbilical cord blood (UCB) transplantation for PIDs is limited.

Purpose of the Study:

• To evaluate the efficacy and safety of UCB transplantation in children with severe PIDs.
• To assess engraftment, immune reconstitution, and survival outcomes in this patient population.

Main Methods:

• Fifteen children with various PIDs received UCB transplants (14 unrelated, 1 related).
• Conditioning regimens included busulfan/cyclophosphamide or fludarabine/melphalan, with some receiving antithymocyte globulin.
• Engraftment, neutrophil recovery, graft-versus-host disease (GvHD), infections, and survival were monitored.

Main Results:

• All 15 patients achieved engraftment, with median neutrophil recovery at 31 days.
• Eight patients developed acute GvHD (grades II-IV), and one had chronic GvHD.
• Four patients died from GvHD complications or interstitial lung disease; five-year survival was 73%.
• Surviving patients showed complete immunologic reconstitution and were independent of IVIg therapy.

Conclusions:

• UCB transplantation is a feasible and effective alternative for pediatric PID patients without HLA-identical sibling donors.
• Successful immune reconstitution and acceptable survival rates support UCB as a valuable option.
• Further research can optimize UCB transplant protocols for pediatric PIDs.